Holen Sie sich die Stockscreener-App
2.12
1.92%
0.04
Handel nachbörslich:
2.16
0.04
+1.89%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.08
Offen:
$2.05
24-Stunden-Volumen:
3.27M
Relative Volume:
1.64
Marktkapitalisierung:
$149.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.34M
KGV:
-1.5588
EPS:
-1.36
Netto-Cashflow:
$-36.91M
1W Leistung:
+14.59%
1M Leistung:
+34.18%
6M Leistung:
+98.13%
1J Leistung:
+89.29%
1-Tages-Spanne:
$1.96
$2.2691
1-Wochen-Bereich:
$1.82
$2.2691
52-Wochen-Spanne:
$0.772
$2.2691
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Firmenname
Sellas Life Sciences Group Inc
Sektor
Branche
Telefon
(646) 200-5278
Adresse
7 TIMES SQUARE, NEW YORK, NY
Vergleichen Sie SLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
2.12 | 149.67M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-07-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-11-01 | Eingeleitet | Oppenheimer | Outperform |
| 2018-04-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-19 | Hochstufung | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Aktie (SLS) Neueste Nachrichten
SELLAS Life Sciences Holds Annual Stockholders Meeting - TipRanks
SELLAS Life Sciences: Tons Of Completed Studies (NASDAQ:SLS) - Seeking Alpha
Insider Buying: VAN NOSTRAND ROBERT L Acquires Additional Shares of SELLAS Life Sciences Group Inc (SLS) - GuruFocus
SELLAS Life Sciences Group Inc (SLS) Stock: A Year of Highs and Lows - investchronicle.com
Sellas Life Sciences director Van Nostrand buys $14,800 in stock By Investing.com - Investing.com South Africa
Sellas Life Sciences director Van Nostrand buys $14,800 in stock - Investing.com
SELLAS adds oncology experts to advisory board By Investing.com - Investing.com South Africa
SELLAS Life Sciences Expands Scientific Advisory Board with - GlobeNewswire
SELLAS Life Sciences Expands Scientific Advisory Board - citybiz
SELLAS adds oncology experts to advisory board - Investing.com
Leading Oncology Experts Join SELLAS Advisory Board as Critical AML Trial Results Near - Stock Titan
Northern Trust Corp Acquires 33,878 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World
Insider Buying: Jane Wasman Acquires 20,000 Shares of SELLAS Lif - GuruFocus
SELLAS reports potential colorectal cancer therapy progress By Investing.com - Investing.com South Africa
SELLAS reports potential colorectal cancer therapy progress - Investing.com India
Insider Buying: Jane Wasman Acquires 20,000 Shares of SELLAS Life Sciences Group Inc (SLS) - GuruFocus
SELLAS Life Sciences (SLS) Highlights Promising Results for SLS0 - GuruFocus
Sellas Life Sciences Group, Inc. Presents Preclinical Efficacy of Sls009 in Asxl1 Mutated Colorectal Cancer At 2025 Asco Annual Meeting - marketscreener.com
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting - GlobeNewswire
Breakthrough at ASCO: SELLAS Drug Shows Powerful Response in Targeted Colorectal Cancer Treatment - Stock Titan
National Bank Financial Comments on CVE:SLS FY2026 Earnings - Defense World
Insider Buying: Katherine Kalin Acquires 20,000 Shares of SELLAS Life Sciences Group Inc (SLS) - GuruFocus
US futures and global markets tumble after Trump threatens European Union with 50% tariffs and Apple with 25% tariff - The Globe and Mail
Director Makes Bold Move with Major Stock Purchase in SELLAS Life Sciences Group - TipRanks
Sellas Life Sciences Reports Improved Financial Position - TipRanks
SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase - The Manila Times
SELLAS Life Sciences CEO to Reveal Latest Cancer Drug Development Strategy at Major Healthcare Conference - Stock Titan
Sellas doses first paediatric subject with AML in Phase II trial of SLS009 - Yahoo Finance
SELLAS advances pediatric AML treatment with Phase 2 trial By Investing.com - Investing.com South Africa
Sellas Life Sciences Doses 1st Pediatric Patient in Acute Myeloid Leukemia Study - marketscreener.com
SELLAS Life Sciences (SLS) Advances Phase 2 Trial for Pediatric AML | SLS Stock News - GuruFocus
SELLAS advances pediatric AML treatment with Phase 2 trial - Investing.com
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML - GlobeNewswire
Breakthrough: First Child with Resistant Leukemia Receives New Treatment in Major Clinical Trial - Stock Titan
SELLAS Life Sciences (SLS) Reports Improved Q1 Earnings Amid Fin - GuruFocus
SLS009 Shows Promising Results in Latest AML Trials | SLS Stock News - GuruFocus
SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
SELLAS Life Sciences Group Reports Positive Overall Survival Data for SLS009 in r/r AML and Updates on Financial Position and Pipeline Developments - Nasdaq
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.
SELLAS Life Sciences Group (SLS) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Upward Trajectory: SELLAS Life Sciences Group Inc (SLS) Posts a Gaine, Closing at 1.72 - DWinneX
Financial Metrics Exploration: Understanding SELLAS Life Sciences Group Inc (SLS) Through Ratios - DWinneX
Geode Capital Management LLC Purchases 128,355 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World
Wall Street analysts’ outlook for SELLAS Life Sciences Group Inc (SLS) - Sete News
SELLAS Life Sciences Group Inc’s latest rating changes from various analysts - knoxdaily.com
SELLAS Life Sciences Group Inc (SLS) Stock: The Story of a 52-Week Stock Range - investchronicle.com
Understanding the Risks of Investing in La Rosa Holdings Corp (LRHC) - knoxdaily.com
SELLAS reports promising AML treatment in preclinical study - Investing.com
Finanzdaten der Sellas Life Sciences Group Inc-Aktie (SLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sellas Life Sciences Group Inc-Aktie (SLS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Wasman Jane | Director |
May 30 '25 |
Buy |
1.69 |
20,000 |
33,800 |
30,400 |
| Kalin Katherine Bach | Director |
May 22 '25 |
Buy |
1.80 |
20,000 |
36,000 |
41,000 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):